Aventis/Novartis Merger Would Infuse New Blood Into Novartis' Cardiology R&D
This article was originally published in The Pink Sheet Daily
The combined cardiovascular portfolio would be a strategic fit since Aventis has focused more on acute indications, while Novartis has targeted chronic conditions. Oncology would be largest therapeutic area.
You may also be interested in...
Novartis' TCH-346 is slated to enter Phase III in the second half of the year; Cephalon/Lundbeck's CEP-1347 is in Phase II/III. Both drugs claim inhibition of neuronal cell death as the primary mechanism, but will need long-term trials for disease-modification claim.
Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.